Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction by Ducharme, Anique et al.
 
Targeted deletion of matrix metalloproteinase-9 attenuates left
ventricular enlargement and collagen accumulation after
experimental myocardial infarction
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ducharme, Anique, Stefan Frantz, Masanori Aikawa, Elena
Rabkin, Merry Lindsey, Luis E. Rohde, Frederick J. Schoen, et al.
2000. “Targeted Deletion of Matrix Metalloproteinase-9
Attenuates Left Ventricular Enlargement and Collagen
Accumulation after Experimental Myocardial Infarction.” J. Clin.
Invest. 106 (1) (July 1): 55–62. doi:10.1172/jci8768.
Published Version doi:10.1172/JCI8768
Accessed February 17, 2015 1:51:53 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13506942
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAIntroduction
The extent of ventricular dilation after a myocardial
infarction (MI) depends on the magnitude of the initial
ischemic damage as well as the tissue healing process 
(1, 2). This dynamic pathological process includes the
expression and activation of the matrix metallopro-
teinases (MMPs), which may mediate many of the mor-
phological changes that occur after MI in both infarct-
ed and noninfarcted regions (3–5). Members of the
MMP family of enzymes degrade specific extracellular
matrix components; clinical and experimental studies
have shown that MMP expression and activity increase
in both MI (5) and dilated cardiomyopathy (6, 7).
Because extracellular matrix deposition and organi-
zation play a major role in left ventricular (LV) remod-
eling, MMP inhibition has emerged as a potential ther-
apeutic strategy for patients at risk for the
development of congestive heart failure. Administra-
tion of a broad-spectrum MMP inhibitor attenuates
LV enlargement in pacing-induced congestive heart
failure (8) and in the early period after MI occurs (9).
Whether this effect depends on the inhibition of many
MMPs, or selective inhibition of MMPs can prevent
ventricular dilation remains unexplored. Recently,
Heymans et al. reported a decreased incidence of rup-
ture at 4 days after MI in MMP-9–deficient animals,
suggesting that MMP-9 may have a specific role in
early myocardial healing (10). In this study we evalu-
ated the influence of targeted deletion of the MMP-9
gene on LV remodeling after experimental MI in mice.
We performed this study with sibling wild-type (WT)
controls after at least six backcrosses to minimize
genetic variability. All analyses were blinded to geno-
type; the animals were studied for 15 days.
Methods
Animals and surgery. We used the progeny of heterozy-
gous breeding pairs of mice with targeted disruption
of MMP-9, as described by Vu et al. (11). MMP-9–defi-
cient mice have delayed long-bone growth and devel-
opment due to delayed angiogenesis and ossification;
however, by adulthood, these changes result in only a
10% shortening in the long bones. Animals with an
FVB background were backcrossed; our studies used
the homozygous MMP-9-deficient and sibling WT off-
spring of generation six or higher. Offspring were ear-
tagged and coded, with tail DNA samples harvested
for genotyping using PCR. For MMP-9, we used a
sense oligonucleotide primer (5¢-GCA TAC TTG TAC
CGC TAT GG -3¢) and an antisense primer (5¢-TAA CCG
GAG GTC CAA ACT GG-3¢). For the neomycin cassette,
we also used a sense oligonucleotide primer (5¢-GAA
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J. Clin. Invest. 106:55–62 (2000).GGG ACT GGC TGC TAT TG-3¢)and an antisense primer
(5¢-AAT ATC ACG GGT AGC CAA CG-3¢). Again, all proce-
dures were performed without knowledge of genotype.
Males with deletion of MMP-9 and WT males, rang-
ing in age from 8 weeks to 10 weeks, and in weight
from 25 grams to 30 grams, underwent coronary
artery ligation for the production of MI. Surgical
procedures have been described in detail elsewhere (9,
12). Briefly, after anesthesia with pentobarbital
(25–30  mg/g intraperitoneally) and intubation with a
polyethylene tube (size 60), animals were ventilated
with a volume-cycled rodent respirator (Harvard
Apparatus Co., South Natick, Massachusetts, USA)
with a 2–3 mL/cycle at a respiratory rate of 115
cycles/min. After thoracotomy, ligation of the left
coronary artery was performed with a 7-0 silk suture,
3–4 mm from the tip of the left auricle. Pallor, region-
al hypokinesia, and enlargement of the left ventricle
confirmed the presence of an infarction. The chest
wall was closed with a continuous 6-0 prolene suture,
and the skin was closed with 4-0 polyester sutures.
The animals were then extubated and allowed to
recover from surgery under a heating lamp for 1
hour. Antibiotic prophylaxis was not given, but no
apparent infection developed in any animal during
the course of the study or at the time of autopsy. All
mice were housed under identical conditions, and
were given food and water ad libitum. The Harvard
Medical School Standing Committee on Animal
Research approved the study protocol.
Echocardiographic imaging. Echocardiographic studies
were performed under light anesthesia with sponta-
neous respiration using intraperitoneal 2,2,2-tribro-
moethanol (Avertin; Aldrich, Milwaukee, Wisconsin,
USA) in a 2.5% wt/vol solution (8 mL/g of mouse) as
previously described (9). An ultrasonographer experi-
enced in rodent imaging performed the echocardio-
graphic studies, using commercially available equip-
ment (Sonos 5500; Hewlett Packard Medical
Products, Andover, Massachusetts, USA) and an 8- to
12-MHz transducer. Dynamically focused annular
array and fusion frequency technologies were used,
allowing ultrasound frequencies of up to 18 MHz. A
standoff was used, depth was set at 4 cm, and the
zoom mode was used to optimize resolution and pen-
etration. Frame acquisition rates using the loop mode
reached up to 120 MHz, allowing excellent temporal
resolution. Identical zoom size and depth settings
were used between examinations to facilitate calibra-
tion for offline analysis.
M-mode images were obtained at a sweep speed of
100 mm/s. Two-dimensional image-guided M-mode
recordings were made at the midpapillary level. Api-
cal image-guided M-mode recordings were obtained
at the greatest area/diameter in the lower third of the
left ventricle. The images were recorded on S-VHS
tapes for offline analysis. Echocardiographic studies
were performed at baseline (18–24 hours after the
surgical procedure), at 4 days, at 8 days, and at 15
days after the surgery, immediately before the sacri-
fice of the animals. We allowed an 18- to 24-hour
recovery period to minimize the residual negative
inotropic and chronotropic effects that may be
encountered after general anesthesia (furthermore,
quality of echocardiographic imaging is not optimal
immediately after a thoracotomy). Echocardiograph-
ic acquisition and analysis was performed by a single
echocardiographer blinded to mouse genotype. End-
diastolic and end-systolic diameters were measured,
and fractional shortening was calculated. For each
measurement, three consecutive cardiac cycles were
measured and averaged.
Tissue collection. Mice were sacrificed after the last
echocardiographic study, on day 15. Hearts were
excised, and the right and left ventricles were separat-
ed. A transverse section (5–7 mm) was obtained at the
midventricular level. Tissue sections were embedded in
OCT compound (Sakura, Torrance, California, USA)
and frozen in 2-methylbutane prechilled with liquid
nitrogen. Tissue blocks were stored at –80°C until sec-
tioning. In a subset of eight animals (4 MMP-9 KO and
4 WT), the left ventricle was divided between the apical
and papillary regions and frozen in liquid nitrogen for
immunoblot analysis.
Northern and Western blots. Total cellular RNA was iso-
lated by a modification of the acid guanidinium thio-
cyanate and phenol/chloroform extraction method,
using TRIzol LS Reagent (Life Technologies Inc.,
Gaithersburg, Maryland, USA) according to the manu-
facturer’s protocol. RNA was size fractionated on 1.0%
agarose, transferred to a nylon membrane, and cross-
linked with ultraviolet radiation. A murine collagen
type IacDNA was radiolabeled using a random primer
labeling kit (Life Technologies Inc.). Normalization of
RNA for equal loading was carried out by rehybridizing
with a murine GAPDH cDNA probe. Autoradiographs
were scanned using version 1.62 of the Image program
from the National Institutes of Health.
For Western analysis, frozen tissue was homogenized
in buffer containing 1% nonylphenol ethoxylate, 0.5%
sodium deoxycholate, 0.1% SDS, and protease inhibitors
in PBS. Equal amounts of the denatured protein from
the supernatant were loaded per lane for SDS-PAGE.
After running the gel, proteins were transferred to a
PVDF membrane. After blocking with 5% nonfat dry
milk in Tris-buffered saline with 0.1% Tween 20, mem-
branes were incubated with antibody against MMP-2,
MMP-3, TIMP-1 (Oncogene; Cambridge, Massachusetts,
USA), or MMP-13 (Chemicon; Temecula, California,
USA) for 60 minutes, followed by washing and incuba-
tion with a matching secondary antibody (Bio-Rad Lab-
oratories Inc., Hercules, California, USA). Membranes
were then incubated with a chemiluminescent agent
(Renaissance; DuPont NEN, Boston, Massachusetts,
USA) and autoradiographed.
Immunocytochemistry. Fresh-frozen sections (6 mm)
were fixed with fresh 4% paraformaldehyde for 10
minutes and rinsed in PBS. Tissue sections were
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inhibit endogenous peroxidase activity, and then
incubated with primary antibodies diluted in PBS,
supplemented with 4% of the species-respective nor-
mal serum for 30 minutes at room temperature. After
washing with PBS, species-appropriate biotinylated
secondary antibodies were applied, followed by
avidin-peroxidase complexes (Vector Laboratories,
Burlingame, California, USA). The reaction was visu-
alized with 3-amino-9-ethyl carbazole as substrate
(AEC; Sigma Chemical Co., St. Louis, Missouri, USA),
and counterstained with Gill’s hematoxylin solution.
The following primary antibodies were used: anti-
mouse neutrophils (Cedarlane Laboratories, Hornby,
Ontario, Canada) and antibodies against human a-
smooth muscle actin (DAKO Corp., Carpinteria, Cal-
ifornia, USA), mouse macrophage Mac-3, and human
endothelial cell CD31, CD4, and CD8 (PharMingen,
San Diego, California, USA). For each section, cells
positive for CD4, CD8, and CD31 were counted in the
infarcted area of mouse heart in at least 7–10 random
high-power fields. To analyze cells that stained posi-
tive for Mac3 and a-smooth muscle actin, a comput-
er-based image analysis was used (see below). Cell
counting and quantitative morphometry were done
by two observers who were unaware of genotype.
Collagen content. Picrosirius red polarization micro-
scopy was performed for detection of interstitial colla-
gen according to Junqueira’s method with our modifi-
cations (13, 14). Birefringence under illumination with
polarized light identifies collagen, including types I
and III (13). Sections from a subset of 15 mice (7 MMP-
9 KO and 8 WT) that survived the 15-day protocol were
chosen; MI sizes were qualitatively similar by Masson’s
trichrome and picrosirius red staining. Fresh-frozen
sections (6 mm) were fixed in 10% neutral buffered for-
malin, rinsed with distilled water, and incubated with
0.1% picrosirius red F3BA (Polysciences Inc., Warren,
Pennsylvania, USA) in saturated picric acid for 90 min-
utes. Sections were rinsed twice with 0.01 N HCl for 1
minute, and then immersed in distilled water. After
dehydration with 70% ethanol for 30 seconds, sections
were visualized under polarized light and pho-
tographed with the same exposure time for each sec-
tion as previously described (14). Two predefined
regions (infarcted and noninfarcted) were chosen and
photographed at low power (´40). A microplate read-
er–based quantitation of collagens was performed as
described by others (15, 16). Briefly, collagen standards
and lysates were plated on microtiter wells in triplicate,
and dried onto the plates. The wells were stained with
0.1% Sirius red F3BA in saturated picric acid for 1 hour,
and washed with 10 mM HCl and 0.1 mM NaOH.
Absorbance was read at 540 nm. Previously, this test
has been shown to be comparable to the colorimetric
hydroxyproline assay (16).
Quantitative analysis for histology. Analysis of immuno-
histochemistry for macrophages, neutrophils, a-actin,
and picrosirius red staining was performed with a
computer-based quantitative 24-bit (16.2 million
unique combinations) color image analysis system
(Optimas 5.2; Optimas Corp., Bothell, Washington,
USA) (17). Micrographs were scanned into a 1,000 ´
1,000 image buffer. A color threshold mask for
immunostaining was defined to detect the red color
by sampling, and the same threshold was applied to
all specimens. The percentage of the total area with
positive color for each section was recorded. For
picrosirius red staining, a negative background
(black) was chosen for thresholding, and the positive
area was calculated by subtraction. Collagen volume
fraction was calculated as the sum of stained tissue
divided by the sum of muscle area and connective tis-
sue in the visual field of the section. This approach
predicts the proportion of myocardium occupied by
fibrillar collagen, and correlates closely with the
hydroxyproline concentration of the tissue (18).
Statistical analysis. In a previous study, we found that
some mice that underwent surgical ligation of the left
coronary artery, despite paleness and bulging of the left
ventricle at the time of surgery, did not develop either
wall-motion abnormalities that were visible by echocar-
diography or histologic evidence of infarction. Not sur-
prisingly, these animals do not demonstrate a progres-
sive increase in LV dimensions (9). Based on these
observations, our study was designed to include in the
statistical analysis only the animals that revealed a wall-
motion abnormality during the baseline study, within
24 hours of the surgical procedure. This determination
was made at the time of the initial echocardiogram
without knowledge of mouse genotype.
The mortality data (deaths occurring soon after sur-
gery and during the 15-day protocol, including causes
of death) were analyzed with the Pearson c2 test. Two-
way repeated-measures mixed-model ANOVA was
used to test differences between groups regarding the
evolution across time of ventricular dilation. When a
possible interaction was found (P < 0.25), slice effects
(also known as simple effects) were analyzed, i.e., time
effect was analyzed for each genotype group, and dif-
ferences between the groups were analyzed for each
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Figure 1
Design of the protocol, with timing of experimental MI, echocardio-
graphic studies, and sacrifice. LCA, left coronary artery. KO, MMP-
9 KO animals; WT, congenic MMP-9 WT animals.level of time. To keep the overall statistical significance
at 5%, the levels of significance for testing simple time
effects were adjusted according to the Bonferronirule.
For comparisons over time after MI, repeated meas-
ures ANOVA was used. To account for the three with-
in-group comparisons, P < 0.0167 was considered sig-
nificant. For between-group comparisons at each
timepoint, a less conservative level was used; P < 0.05
was considered significant. All the analyses were per-
formed with the MIXED procedure of SAS 6.12 (SAS
Institute Inc., Cary, North Carolina, USA) to handle
missing data. All values are expressed as mean ± SD.
Results
Operative mortality and baseline measurements. Ninety-
seven mice survived the surgical procedure (56 WT
and 41 KO); early operative mortality (within 24
hours) was 11% (7 WT and 4 MMP-9 KO; P = 0.67).
The 86 animals that survived 24 hours after surgery
underwent transthoracic echocardiography for base-
line imaging (Figure 1, Table 1). Infarction, as
defined by wall-motion abnormality, was achieved in
78% of the procedures (n = 65, 34 WT and 31 MMP-
9 KO). Among the infarcted animals, 25 deaths
(38.5%) occurred during the 15-day protocol (14 WT
and 11 MMP-9 KO; P = 0.91). All mice that died and
were included in the MI group were confirmed to
have MI by postmortem examination. Death was
attributed to congestive heart failure or arrhythmia
(or both) in all cases, except for five animals that
died from LV rupture, as defined by extensive blood
surrounding the heart or filling the chest cavity (4
WT and 1 KO; P = 0.28). Baseline echocardiographic
measurements of infarcted mice were similar in both
groups. There was a small but statistically signifi-
cant increase in LV end-diastolic dimension at base-
line between the MMP-9 KO and WT groups. Based
on previous data suggesting that larger ventricles at
baseline are more likely to dilate with time (9), this
represented a modest bias toward the null hypothe-
sis; that is, the MMP-9 KO group would be more
likely to have progressive enlargement.
Followup echocardiographic measurements (Table 2). Four
days after MI, the two groups exhibited similar increases
in end-systolic and end-diastolic diameters compared
with baseline measurements. In contrast, 8 days after MI,
both midpapillary and apical end-diastolic and end-sys-
tolic diameters increased in the WT group, with negligi-
ble changes in the MMP-9 KO mice. This attenuation of
enlargement in MMP-9 KO mice continued at 15 days.
During the 15-day protocol, resting heart rate increased
from baseline over time in both groups, but there were no
significant differences between the two groups.
Animals with no obvious cardiac enlargement or
wall-motion abnormalities during the baseline
echocardiogram were not included in the statistical
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Figure 2
(a) Representative examples of staining with Masson’s trichrome and picrosirius red under polarized light of the infarcted region, 15 days
after experimental MI (WT is represented by the left panels, MMP-9 KO by the right panels). Picrosirius red staining demonstrated the char-
acteristic bright yellow of collagen fibrils under polarized light, with less deposition of picrosirius red–stained collagen in MMP-9 KO sam-
ples than in WT samples (scale bar: 200 mm). (b) Collagen volume fraction from picrosirius red–stained myocardium as percentage of stained
tissue in muscle areas and connective tissue in the visual field of the section. (c) Collagen content of apical myocardium after MI in infarct
size matching WT and KO animals. AP < 0.05.analysis, but were followed for the 15-day protocol and
analyzed separately (n = 21). There were 16 “unintend-
ed shams” in the WT group, and 5 in the MMP-9 KO
group (P < 0.001). These mice showed no ventricular
dilation during the 15-day protocol (data not shown).
Collagen analysis. Masson’s trichrome staining and
picrosirius red polarization for collagen was per-
formed 15 days after infarction to test the hypothesis
that deletion of MMP-9 changed deposition of colla-
gen of the infarcted area (Figure 2). As expected, quan-
titative analysis for picrosirius red polarization
showed that collagen fractional area was significant-
ly greater in the infarcted region than in the nonin-
farcted region, irrespective of genotype (64.4 ±9.7% vs.
13.0 ± 5.5%; P < 0.0001; n = 15). Collagen fractional
area in the noninfarcted region of the heart was not
different between the two groups (14.7 ±5.5% vs. 11.5
± 5.4%; P = 0.28). However, MMP-9 KO mice had sig-
nificantly less collagen accumulation in the infarcted
region than did WT mice (collagen fractional area
58.6 ± 7.8% vs. 69.6 ± 8.4%, respectively; n = 15; 
P = 0.02). In addition to an increase in the total con-
tent, the collagen appeared more organized, with
thicker fibers in the WT mice than in the MMP-9 KO
mice. Moreover, quantitation of collagen showed sig-
nificantly less collagen accumulation in the MMP-9
KO mice than in WT controls matched by infarct size
(WT, 1.09 ± 0.06 vs. KO, 0.73 ± 0.08 mg/ml KO; 
P = 0.01). Collagen type Ia gene expression was not
different between the groups (collagen type
Ia/GAPDH: WT, 1.0 ± 0.1 vs. KO, 0.9 ± 0.2; P = 0.82,
arbitrary units; data not shown). Thus, the reduced
collagen level in MMP-9 KO animals is consistent
with increased collagen degradation.
Immunohistochemistry. The infarcted region contained
numerous macrophages identified by immunoreactive
Mac3 throughout the infarcted segments (Figure 3).
The number of macrophages increased steadily from
day 1 to day 15. At day 15 there was a reduction in
macrophage number in MMP-9 KO mice compared
with WT mice, as determined by quantitative, comput-
er-assisted image analysis in the infarcted region (pos-
itive fractional area of 22.0 ± 5.3% in MMP-9 KO mice
vs. 34.3 ± 8.9% in WT mice; P = 0.013; n = 11). 
Neutrophils increased from day 1 to day 7, with a
greater increase in the WT mice (31.1 ± 15.1% in WT
vs. 12.6 ± 11.1% in MMP-9 KO; P = 0.16; n = 6). There
were no differences in densities of CD4- or CD8-pos-
itive cells between MMP-9 KO and WT mice, suggest-
ing that T-cell infiltration was not affected by the
absence of MMP-9. Smooth muscle cells immunore-
active for a-actin were decreased in microvessels in
MMP-9 KO mice (79.8 ± 28.3 per section) compared
with WT mice (104.1 ± 23.8 per section; P = 0.07; 
n = 11). A similar trend was found in the number of
microvessels detected by CD31 antibody (77.8 ± 94.7
per section in MMP-9 KO mice vs. 151.2 ± 44.2 per
section in WT mice; P = 0.10; n = 11).
Western analysis. MMPs have overlapping substrate
specificities, so the effect of loss of specific activities of
one enzyme can possibly be reduced by compensation
by other enzymes. To test the hypothesis that MMP-9
deletion may affect expression of other MMPs, Western
analyses of tissue extracts were performed. Animals
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Table 1
Baseline echocardiographic measurements of infarcted mice
MMP-9 KO WT
n = 31 n = 34
Midpapillary measurements
ED diameter (mm) 2.8 ± 0.3 2.6 ± 0.3A
ES diameter (mm) 1.8 ± 0.4 1.6 ± 0.4
M-mode FS (%) 37.3 ± 9.2 38.3 ± 12.5
Apical measurements
ED diameter (mm) 2.8 ± 0.3 2.7 ± 0.4
ES diameter (mm) 2.1 ± 0.5 1.9 ± 0.6
M-mode FS (%) 24.5 ± 11 29.5 ± 16
ED, end-diastolic; ES, end-systolic; FS, fractional shortening. Data are
expressed as mean ± SD. AP < 0.01; otherwise, there were no significant dif-
ferences between MMP-9 KO mice and WT mice at baseline.
Table 2
Sequential changes in echocardiographic measurements of infarcted mice from day 1 to day 15 
Measurement Day 4 Day 8 Day 15
MMP-9 KO WT MMP-9 KO WT MMP-9 KO WT
n = 25 n = 25 n = 20 n = 24 n = 20 n = 20
Midpapillary 
D ED diameter (mm)  0.0 ± 0.4 0.1 ± 0.4 –0.1 ± 0.4A 0.4 ± 0.2 0.07 ± 0.4A 0.5 ± 0.4
D ES diameter (mm)  0.05 ± 0.5 0.0 ± 0.7 0.0 ± 0.6B 0.3 ± 0.5 0.04 ± 0.5C 0.3 ± 0.5
D % M-mode FS  –2.0 ± 14.8 2.5 ± 19.1 –1.0 ± 14.7 –2.0 ± 15.4 0.1 ± 14.3 0.4 ± 14.9
Apical 
D ED diameter (mm)  0.2 ± 0.3 0.3 ± 0.5 0.2 ± 0.4C 0.5 ± 0.3 0.3  ±  0.5B 0.7 ± 0.6
D ES diameter (mm)  0.1 ± 0.5 0.3 ± 0.6 –0.1 ± 0.6C 0.5 ± 0.4 –0.1  ± 0.7D 0.6 ± 0.7
D % M-mode FS  1.7 ± 13.7 –2.0 ± 14.5 7.0 ± 15.7E –4.0 ± 11.0 11.2 ± 18.3D –6.0 ± 17.2
All measurements are changes compared with baseline measurements. Data are expressed as mean ± SD. Statistical analyses are MMP-9 KO vs. WT.
AP < 0.0005; BP £ 0.05; CP £ 0.01; DP < 0.005; EP = 0.06.that were not operated on showed no differences in the
expression of MMP-2 and TIMP-1; however, expression
of MMP-3 and MMP-13 were elevated in KO mice (fold
increases respectively 1.7 ± 0.1 [P = 0.02] and 2.1 ± 0.1
[P < 0.01]) (Figure 4). After MI there was increased
expression of MMP-2 (fold increase, 2.1 ±0.3; P< 0.05),
MMP-3 (fold increase, 1.7 ±0.3; P= NS), MMP-13 (fold
increase, 3.3 ±0.9; P< 0.05), and TIMP-1 (fold increase,
2.1 ± 0.3; P < 0.05) in the extracts of MMP-9 KO mice
compared with WT mice (Figure 4). These data suggest
that MMP-9 may play a role in regulating the expres-
sion of other MMPs.
Discussion
LV enlargement after MI is an important clinical deter-
minant of morbidity and mortality (19–21). This study
demonstrated that targeted deletion of the MMP-9gene
attenuates LV enlargement after experimental MI in
mice. Differences in collagen accumulation within the
infarcted heart, associated with enhanced expression of
some MMPs, may contribute to this effect. These data
suggest that individual MMPs may be therapeutic tar-
gets for LV dilation after MI.
The wound repair process involves temporally over-
lapping phases, including inflammation, new tissue
formation, and tissue remodeling (22). During the
inflammatory phase, collagen and other extracellular-
matrix components may be degraded. At that time,
MMP-9 is expressed primarily in myeloperoxidase-pos-
itive or CD45-positive leukocytes and in Mac-3–posi-
tive macrophages (10). We did not find any change in
echocardiographically detectable LV remodeling in
this earliest wound healing phase (at day 4). This
observation suggests that MMP-9 does not play a
major role in the earliest inflammatory phase. It
should be noted that these animals underwent total
coronary occlusion, and the influence of MMP-9 on
the inflammatory process of ischemia and reperfusion
was not evaluated in this study.
By day 15, there was a decrease in macrophage accu-
mulation in the infarcted region of left ventricles of
MMP-9 KO animals. Macrophages have a pivotal role
in the transition between inflammation and repair;
they participate in the wound-healing process
through matrix degradation, neovascularization, and
recruitment and proliferation of fibroblasts (22).
Macrophages express many growth factors, including
PDGF, basic FGF, TGF-a and -b, and TNF-a (23–26).
This finding raises the hypothesis that MMP-9 affects
ventricular remodeling through recruitment of
macrophages. In contrast, we and others found that
neutrophil migration does not require MMP-9 (27).
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Figure 3
(a) Representative examples of staining of a-actin (´400) and macrophages (Mac3, ´100; scale bar: 200 mm) of the infarcted region 15
days after MI, and quantitative fractional areas of (b) macrophages and (c) neutrophils from day 1 to day 7 after MI. AP < 0.05. (d) a-actin
fractional area at day 15.MMPs and TIMPs are overexpressed in ventricles of
patients and animals with congestive heart failure
(4–7). Immunoblotting showed enhanced expression
of MMP-2, MMP-13, and TIMP-1 in the infarcted api-
cal region of the MMP-9–deficient mice. Interesting-
ly, even animals that were not operated on showed ele-
vated protein levels of MMP-3 and MMP-13, but not
MMP-2 or TIMP-1. The cause for this “compensatory”
regulation of other MMPs is not known. Upregula-
tion of MMPs has been reported in MMP-7 KO mice
that were not operated on (28). A likely hypothesis is
that MMP-9 has an in vivo substrate that can provide
specific induction of at least MMP-3 and MMP-13.
Because the dominant MMP in vivo substrates are not
known, the specific mechanism remains to be deter-
mined. In addition, numerous stimuli can promote
MMP expression, including reactive oxygen species,
changes in cell shape, cytokines, growth factors, and
phorbol esters (29). These data suggest that MMP-9
participates in an interacting network of MMP regu-
lation, and that deletion of MMP-9 may lead to
enhanced expression of other MMPs that could be
partially compensatory.
During morphogenesis, MMPs and TIMPs are spa-
tially and temporally regulated (30). MMPs are promi-
nently overexpressed in the wound-repair process, and
are under intense investigation as therapeutic targets
for inflammatory arthritis and cancer (31, 32). One
theme that is emerging from recent studies is that the
apparent redundancy of substrates among MMP fam-
ily members may allow one member of the family to
substitute for another during normal processes such as
development. In contrast, during pathologic circum-
stances, deficiency of a single MMP family member
may lead to profound consequences (30, 33).
An unanticipated finding of this study was
decreased accumulation of interstitial collagen in the
infarcted region of the MMP-9 KO animals compared
with that in WT siblings. Scar formation involves the
interaction of macrophages, myofibroblasts, extracel-
lular matrix components, and cytokines. Collagen
remodeling is a dynamic process that depends on con-
tinuous synthesis, organization, and catabolism (34).
However, because there were no differences in colla-
gen type 1a mRNA, but increased MMP protein con-
tent in MMP-9 KO animals after MI, increased colla-
gen degradation is probably responsible for the
decreased collagen accumulation in MMP-9 KO ani-
mals. Nevertheless, how this decrease in collagen con-
tent might influence wall diameters is not clear.
Because the chamber diameters depend on many fac-
tors, we cannot directly assume that collagen content
alone led to the differences in diameter.
Heymans et al. reported that MMP-9–deficient mice
have reduced cardiac rupture compared with WT mice
(10). A reduction in leukocyte infiltration was observed
after MI in MMP-9–deficient animals compared with
WT animals. In our study, a trend toward reduced car-
diac rupture was noted, but this trend did not reach sta-
tistical significance. One difference between the Hey-
man study and our study is that our WT rupture rate
was much lower, possibly due to surgical technique.
Because we used sibling controls of heterozygous mat-
ing pairs and attempted to achieve a uniform genetic
background by at leastsix backcrosses, it is unlikely that
background effects between the MMP-9 KO and WT
groups influenced the results of our study.
The attenuated dilation, decreased collagen accu-
mulation, and reduced early cardiac rupture associat-
ed with deletion of MMP-9 are theoretically beneficial
events; future studies may determine the potential of
MMP-9 as a therapeutic target. The persistence of
inflammation at 15 days in our study demonstrates
that the inflammatory phase was not yet complete, so
it is possible that MMP-9 KO animals may have either
accelerated or reduced dilation after this time. Our
study was not designed to address the long-term func-
tional or survival implications of MMP-9 or LV func-
tional properties. These data suggest, however, that
MMPs actively participate in remodeling ventricular
tissues after MI, and that specific MMPs have promi-
nent roles in this process.
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Figure 4
Western analysis for MMP-2, MMP-3, MMP-13, and TIMP-1 in ani-
mals that were not operated on (left panel) or 15 days after MI (right
panel). MMP-9 KO mice had increased expression of these MMPs
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